vs
Coeur Mining, Inc.（CDE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Coeur Mining, Inc.的1.1倍（$772.1M vs $674.8M），Coeur Mining, Inc.净利率更高（31.9% vs 12.7%，领先19.1%），Coeur Mining, Inc.同比增速更快（120.9% vs 5.9%），Coeur Mining, Inc.自由现金流更多（$313.3M vs $161.8M），过去两年Coeur Mining, Inc.的营收复合增速更高（78.0% vs 9.0%）
Coeur Mining, Inc.是纽交所上市的贵金属开采企业，在北美运营五座矿山，拥有员工2200名。2012年该公司为全球第九大白银生产商，2013年由原名称Coeur d'Alene Mines正式更名，总部也从爱达荷州科达伦迁至伊利诺伊州芝加哥。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CDE vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$674.8M
营收增速更快
CDE
高出115.1%
5.9%
净利率更高
CDE
高出19.1%
12.7%
自由现金流更多
CDE
多$151.5M
$161.8M
两年增速更快
CDE
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $674.8M | $772.1M |
| 净利润 | $215.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 48.6% | 14.5% |
| 净利率 | 31.9% | 12.7% |
| 营收同比 | 120.9% | 5.9% |
| 净利润同比 | 467.9% | 3.9% |
| 每股收益（稀释后） | $0.37 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDERVTY
| Q4 25 | $674.8M | $772.1M | ||
| Q3 25 | $554.6M | $698.9M | ||
| Q2 25 | $480.6M | $720.3M | ||
| Q1 25 | $360.1M | $664.8M | ||
| Q4 24 | $305.4M | $729.4M | ||
| Q3 24 | $313.5M | $684.0M | ||
| Q2 24 | $222.0M | $691.7M | ||
| Q1 24 | $213.1M | $649.9M |
净利润CDERVTY
| Q4 25 | $215.0M | $98.4M | ||
| Q3 25 | $266.8M | $46.7M | ||
| Q2 25 | $70.7M | $53.9M | ||
| Q1 25 | $33.4M | $42.2M | ||
| Q4 24 | $37.9M | $94.6M | ||
| Q3 24 | $48.7M | $94.4M | ||
| Q2 24 | $1.4M | $55.4M | ||
| Q1 24 | $-29.1M | $26.0M |
毛利率CDERVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CDERVTY
| Q4 25 | 48.6% | 14.5% | ||
| Q3 25 | 31.9% | 11.7% | ||
| Q2 25 | 29.1% | 12.6% | ||
| Q1 25 | 17.3% | 10.9% | ||
| Q4 24 | 21.8% | 16.3% | ||
| Q3 24 | 26.9% | 14.3% | ||
| Q2 24 | 7.5% | 12.4% | ||
| Q1 24 | -1.6% | 6.8% |
净利率CDERVTY
| Q4 25 | 31.9% | 12.7% | ||
| Q3 25 | 48.1% | 6.7% | ||
| Q2 25 | 14.7% | 7.5% | ||
| Q1 25 | 9.3% | 6.4% | ||
| Q4 24 | 12.4% | 13.0% | ||
| Q3 24 | 15.5% | 13.8% | ||
| Q2 24 | 0.6% | 8.0% | ||
| Q1 24 | -13.7% | 4.0% |
每股收益（稀释后）CDERVTY
| Q4 25 | $0.37 | $0.86 | ||
| Q3 25 | $0.41 | $0.40 | ||
| Q2 25 | $0.11 | $0.46 | ||
| Q1 25 | $0.06 | $0.35 | ||
| Q4 24 | $0.11 | $0.77 | ||
| Q3 24 | $0.12 | $0.77 | ||
| Q2 24 | $0.00 | $0.45 | ||
| Q1 24 | $-0.08 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $553.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $7.3B |
| 总资产 | $4.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDERVTY
| Q4 25 | $553.6M | $919.9M | ||
| Q3 25 | $266.3M | $931.4M | ||
| Q2 25 | $111.6M | $991.8M | ||
| Q1 25 | $77.6M | $1.1B | ||
| Q4 24 | $55.1M | $1.2B | ||
| Q3 24 | $76.9M | $1.2B | ||
| Q2 24 | $74.1M | $2.0B | ||
| Q1 24 | $67.5M | $1.7B |
股东权益CDERVTY
| Q4 25 | $3.3B | $7.3B | ||
| Q3 25 | $3.1B | $7.4B | ||
| Q2 25 | $2.8B | $7.6B | ||
| Q1 25 | $2.7B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产CDERVTY
| Q4 25 | $4.7B | $12.2B | ||
| Q3 25 | $4.5B | $12.1B | ||
| Q2 25 | $4.2B | $12.4B | ||
| Q1 25 | $4.1B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.2B | $12.8B | ||
| Q2 24 | $2.1B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $374.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $313.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 46.4% | 21.0% |
| 资本支出强度资本支出/营收 | 9.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.74× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $665.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CDERVTY
| Q4 25 | $374.6M | $182.0M | ||
| Q3 25 | $237.7M | $138.5M | ||
| Q2 25 | $207.0M | $134.3M | ||
| Q1 25 | $67.6M | $128.2M | ||
| Q4 24 | $63.8M | $174.2M | ||
| Q3 24 | $111.1M | $147.9M | ||
| Q2 24 | $15.2M | $158.6M | ||
| Q1 24 | $-15.9M | $147.6M |
自由现金流CDERVTY
| Q4 25 | $313.3M | $161.8M | ||
| Q3 25 | $188.7M | $120.0M | ||
| Q2 25 | $146.1M | $115.5M | ||
| Q1 25 | $17.6M | $112.2M | ||
| Q4 24 | $16.1M | $149.8M | ||
| Q3 24 | $69.1M | $125.6M | ||
| Q2 24 | $-36.2M | $136.6M | ||
| Q1 24 | $-58.0M | $129.7M |
自由现金流率CDERVTY
| Q4 25 | 46.4% | 21.0% | ||
| Q3 25 | 34.0% | 17.2% | ||
| Q2 25 | 30.4% | 16.0% | ||
| Q1 25 | 4.9% | 16.9% | ||
| Q4 24 | 5.3% | 20.5% | ||
| Q3 24 | 22.0% | 18.4% | ||
| Q2 24 | -16.3% | 19.7% | ||
| Q1 24 | -27.2% | 20.0% |
资本支出强度CDERVTY
| Q4 25 | 9.1% | 2.6% | ||
| Q3 25 | 8.8% | 2.6% | ||
| Q2 25 | 12.7% | 2.6% | ||
| Q1 25 | 13.9% | 2.4% | ||
| Q4 24 | 15.6% | 3.4% | ||
| Q3 24 | 13.4% | 3.3% | ||
| Q2 24 | 23.2% | 3.2% | ||
| Q1 24 | 19.8% | 2.7% |
现金转化率CDERVTY
| Q4 25 | 1.74× | 1.85× | ||
| Q3 25 | 0.89× | 2.97× | ||
| Q2 25 | 2.93× | 2.49× | ||
| Q1 25 | 2.03× | 3.03× | ||
| Q4 24 | 1.69× | 1.84× | ||
| Q3 24 | 2.28× | 1.57× | ||
| Q2 24 | 10.69× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDE
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
